TuHURA Biosciences, Inc. (HURA)
NASDAQ: HURA · Real-Time Price · USD
4.880
+0.030 (0.62%)
At close: Feb 4, 2025, 4:00 PM
4.850
-0.030 (-0.61%)
After-hours: Feb 4, 2025, 5:06 PM EST
TuHURA Biosciences Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for TuHURA Biosciences stock has a target of 11, which predicts an increase of 125.41% from the current stock price of 4.88.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 19, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for TuHURA Biosciences is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Dec '24 | Jan '25 |
---|---|---|
Strong Buy | 1 | 1 |
Buy | 0 | 0 |
Hold | 0 | 0 |
Sell | 0 | 0 |
Strong Sell | 0 | 0 |
Total | 1 | 1 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +125.41% | Dec 19, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.47
from -0.43
EPS Next Year
-0.43
from -0.47
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | n/a | n/a | 22.1M | |||
Avg | n/a | n/a | 10.7M | |||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | - | |||
Avg | - | - | - | |||
Low | - | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|
High | -0.48 | -0.44 | -0.30 | |
Avg | -0.47 | -0.43 | -0.30 | |
Low | -0.45 | -0.41 | -0.28 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|
High | - | - | - | |
Avg | - | - | - | |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.